Endpoints News 2026년 4월 2일 Novo and Lilly battle over GLP-1 claims only a head-to-head trial can answer
Endpoints News 2026년 4월 2일 Eli Lilly's chief technology officer retires after 35 years; Astellas strategy exec resigns
Endpoints News 2026년 4월 1일 Lilly wins approval of anti-obesity pill orforglipron, setting up new battle with Novo
Endpoints News 2026년 3월 20일 UK’s NICE revisits Lilly, Eisai Alzheimer's drugs under new pricing threshold
Endpoints News 2026년 3월 19일 Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
Endpoints News 2026년 3월 12일 Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Endpoints News 2026년 3월 11일 Lilly plots GLP-1 pill production boost in China, $500M pledge to South Korea
Endpoints News 2026년 3월 6일 Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
Endpoints News 2026년 2월 24일 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Endpoints News 2026년 2월 23일 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial